Skip to main content
OpenTrials
Completed

NCT Number: NCT01562145

Elevated Plasma Levels of TIMP-1 in Patients With Rotator Cuff Tear

The aim of the study was to investigate the levels of matrixmetalloproteinases and their inhibitors in blood samples from patients with rotator cuff tears and compare with blood samples from healthy matched controls.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rotator Cuff Tear Rotator Cuff Injuries Rupture Shoulder Injuries Tendon Injuries Wounds and Injuries

Sex eligibility

All sexes

Study type

Observational

Primary location

University clinic of orthopeadics Linkoeping

Linköping, Östergötland County, 581 85, Sweden

About this study

Background: Extracellular matrix remodeling is altered in rotator cuff tears, partly due to altered expression of matrix metalloproteinases (MMPs) and their inhibitors. It is unclear if this altered expression can be traced as changes in plasma protein levels. We measured the plasma level of MMPs and their tissue inhibitors (TIMPs) in patients with rotator cuff tears.

Material and methods: Blood samples were collected from 17 patients, median 61 (range 39-77) years, with sonographically verified rotator cuff tears (partial- or full-thickness). These were compared with 16 gender and age matched control persons with sonographically intact rotator cuffs. Plasma levels of MMPs and TIMPs were measured simultaneously using Luminex technology.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • degenerative rotator cuff tear verified by ultrasound

Exclusion criteria

  • systemic joint disease such as rheumatoid arthritis
  • a fracture non-union
  • dupuytrens disease
  • frozen shoulder
  • tendinosis or rupture of any other tendons than in the rotator cuff
  • disorders of the spine such as disc disease,idiopathic scoliosis, spondylitis
  • cerebral or cardiovascular disease during the past year
  • abdominal or bowel disease
  • surgery or trauma during the past year
  • any infection during the last month
  • malignancy
  • treatment for the last month with medications that may affect MMPs or TIMPs (tetracycline, bisphosphonates, anti-inflammatory drugs, statins)
  • vigorous physical activity during the last 24 hours
  • inability to understand written and spoken Swedish

Treatment and study plan

blood sampling

Procedure

Four mL venous blood samples were collected from all study participants after inclusion

Primary outcomes

  1. Level of MMP and TIMP in plasma

    Time frame: Measaured at one time point

    Four mL venous blood samples were collected from all study participants after inclusion, and centrifuged to plasma that was stored at -70 degrees until the analysis.

Sponsors and collaborators

Lead sponsor

University Hospital, Linkoeping

Other

Registry information

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Mar 23, 2012
Registry last updated
Mar 26, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.